Edgewise Therapeutics, Inc. (EWTX): Shareholders' Equity
$522.26M
As of 2025-12-31
$448.08M
As of 2026-06-30
+14.6%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $522.26M | +13.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $459.22M | +44.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $318.83M | -8.0% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $346.72M | +26.4% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $274.38M | n/m | 2023-02-23, Balance as of period end |
| 2020-12-31 | -$33.42M | n/a | 2022-02-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $522.26M | +13.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $424.29M | -10.1% |
| Geron Corp (GERN) | 2025-12-31 | $225.87M | -19.4% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $478.56M | +17.0% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $493.40M | +40.0% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $391.48M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $484.65M | +58.7% |
Compare EWTX, LAB, GERN, OLMA side by side · Screen every company in Pharmaceutical Preparations ↗